15
Apr

A few months ago Roche put out the word that its schizophrenia drug bitopertin had flunked the first two Phase III studies in a lengthy lineup of clinical trials. And today the pharma giant almost completed its obituary for a drug program that had been touted as one of Roche’s top blockbuster prospects, adding a long slate of trial flops to the record.

…read more

Source: Roche adds a slate of PhIII schizophrenia trial failures to bitopertin’s obituary

    

0 No comments